Autopsy report · NCT01147016

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

“Primary co-investigator leaving the institution \& funding transfer.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 7 years before it stopped.
• 8 participants enrolled.
• Results were posted on the registry 5 years 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Barbara Ann Karmanos Cancer Institute

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

HER2Bi-armed activated T cells; cyclophosphamide; doxorubicin hydrochloride; paclitaxel; laboratory biomarker analysis; neoadjuvant therapy

Participants

8

Sites

1

Countries

United States

Trials that died the same way

• Study of Antibiotics in Cerebrospinal Fluid Following Intravenous Injection
  “Primary investigator left institution” (80% match in meaning)
• Use of Cast Iron Pots to Improve Maternal Anemia
  “Original investigator has left the institution.” (77% match in meaning)
• Impact of Statins on Cytokine Expression in Pneumonia
  “Investigator left institution.” (76% match in meaning)
• Effect of Virtual Reality Training by Novices on Laparoscopic Cholecystectomy in a Porcine Model
  “Principal investigator left institution.” (76% match in meaning)
• Intralesional Tetracycline Injection in the Treatment of Chalazia
  “Investigator left the institution” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.